Unlearn.AI

What it does

Unlearn.AI is an AI-native clinical trial optimization company that creates 'digital twins' of clinical trial patients - AI-generated models that predict how specific patients would progress without treatment, based on their baseline characteristics and historical patient data. By using these digital twins as synthetic control arms, pharma companies can run clinical trials with smaller placebo groups, reducing patient exposure to ineffective treatments, accelerating trial timelines, and lowering trial costs. Unlearn's approach has received regulatory acceptance - the FDA and EMA have cleared the use of Unlearn's prognostic covariate methodology in specific trial designs - making it a scientifically credible approach to clinical trial optimization.

Strengths

• Pharmaceutical and biotech companies use Unlearn.AI to reduce clinical trial costs and patient burden - AI-generated synthetic controls enabling smaller placebo arms while maintaining statistical power.
• Unlearn.AI is an AI-native clinical trial optimization company that creates 'digital twins' of clinical trial patients - AI-generated models that predict how specific patients would progress without treatment, based on their baseline characteristics and historical patient data.
• By using these digital twins as synthetic control arms, pharma companies can run clinical trials with smaller placebo groups, reducing patient exposure to ineffective treatments, accelerating trial timelines, and lowering trial costs.

Watch-outs

• Regulatory acceptance is disease and design specific: Unlearn's methodology has regulatory acceptance in specific disease areas and trial designs — applicability to novel disease areas or unusual trial designs requires validation with regulatory agencies.
• Requires historical patient data: Digital twin generation accuracy depends on the depth and quality of historical patient data — rare diseases or novel patient populations with limited historical data produce less accurate digital twins.
• Niche clinical trial application: Unlearn.AI addresses a specific problem in clinical trial design — its value is clear for late-stage drug development but limited for preclinical research or discovery-phase applications.

Pricing

Unlearn.AI does not publish standard pricing. Contracts with pharmaceutical companies are based on trial scope and disease area. Enterprise contracts typically start in the six-figure range per trial.